Roivant Sciences Ltd.·4

Feb 11, 5:53 PM ET

Sukhatme Mayukh 4

4 · Roivant Sciences Ltd. · Filed Feb 11, 2026

Research Summary

AI-generated summary of this filing

Updated

Roivant (ROIV) President Mayukh Sukhatme Exercises Options, Sells Shares

What Happened
Mayukh Sukhatme, President & Chief Investment Officer and a director of Roivant Sciences (ROIV), exercised 651,558 stock options and on the same day disposed of the 651,558 underlying common shares. The exercise reported a weighted-average exercise price of $12.68 (total cost ≈ $8.26M). The shares were sold in two reported dispositions: 339,441 shares in open-market transactions at a weighted price of $26.47 (proceeds ≈ $8.99M) and 312,117 shares in an “other disposition” reported at $26.47 (proceeds ≈ $8.26M). Total gross sale proceeds were about $17.25M.

Key Details

  • Transaction date: February 9, 2026 (reported on Form 4 filed Feb 11, 2026). No late filing noted in the report.
  • Exercise: 651,558 options exercised (Code M) at a weighted-average price $12.68; exercise cost ≈ $8,261,755.
  • Sales: 339,441 shares sold in open market (Code S) and 312,117 shares disposed (Code J), both reported at $26.47 (total sales ≈ $17,246,740). Footnote indicates sales executed at prices ranging $25.92–$26.78.
  • Net/settlement detail: Footnotes state the issuer completed a “net settlement” of options to satisfy the exercise price (i.e., some shares were used to cover exercise/tax obligations). One derivative line at $0 reflects that net settlement.
  • Footnotes: F1 notes the weighted-average price and offers to provide breakouts on request; F2 gives the sale-price range; F3 confirms net settlement by the issuer; F4 references a fully vested award.
  • Shares owned after the transactions: not specified in the provided filing excerpt.

Context

  • This was an options exercise followed by sales (a common practice when in-the-money options are exercised near expiration). Footnote F1 indicates the options would have expired in March 2026 if not exercised.
  • The combination of exercise + immediate sale (including net settlement) typically reflects exercising options to capture intrinsic value and covering exercise/tax costs, rather than a new purchase signal. This Form 4 is factual reporting of those transactions and does not by itself indicate insider intent.

Insider Transaction Report

Form 4
Period: 2026-02-09
Sukhatme Mayukh
DirectorPresident & CIO
Transactions
  • Exercise/Conversion

    Common Shares

    2026-02-09$12.68/sh+651,558$8,261,75519,488,105 total
  • Sale

    Common Shares

    [F1][F2]
    2026-02-09$26.47/sh339,441$8,985,00319,148,664 total
  • Other

    Common Shares

    [F3][F1]
    2026-02-09$26.47/sh312,117$8,261,73718,836,547 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F4]
    2026-02-09651,5580 total
    Exercise: $12.68Exp: 2026-03-31Common Shares (651,558 underlying)
Footnotes (4)
  • [F1]All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  • [F2]These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive.
  • [F3]Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
  • [F4]Award of stock options to purchase Common Shares that is fully vested.
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme|2026-02-11

Documents

1 file
  • 4
    wk-form4_1770850398.xmlPrimary

    FORM 4